San Diego and Melbourne, Australia - JANUARY 31, 2019 - Okogen, a clinical-stage, specialty biotechnology company focused on developing ophthalmic therapeutics, today announced the initiation of a Phase 2 clinical trial (RUBY) that is designed to evaluate the safety and effica...

February 27, 2018 -- San Diego, CA -- Okogen, Inc., a developer of ophthalmic anti-infective drugs, announced $10 million in Series A funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) to advance the ongoing development of the company’s lead candidat...